Scientific Advisory Board
Dr. Hearst is a Founder of Cerus Corporation and served on its Board of Directors from 1990 to 2001. Dr. Hearst was a Professor of Chemistry at U.C. Berkeley for 35 years. He has studied the basic mechanisms of molecular biology including transcription, translation, psoralen photochemistry, DNA excision repair, photosynthesis, and DNA structure and elasticity. His techniques are presently being applied to the improvement of stem cell transplantation and for the development of vaccines. He obtained a B.Eng. degree in Chemical Engineering from Yale University, and a Ph.D. in Chemistry and Physics from the California Institute of Technology.
Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon), University of California, San Francisco
Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) is the Director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and clinical care organization that is one of the largest cancer centers in the Western United States, and he is Associate Dean of the UCSF School of Medicine. A native of Cambridge, England, Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham (1972) and his Ph.D. in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the US at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund.
He has been a Fellow of the Royal Society since 1996. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including positions with Cetus Corporation (Director of Molecular Biology, 1981-90; Vice President of Research, 1990-91) and Chiron Corporation, where he was Vice President of Research from 1991-92.
In 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. Dr. McCormick's current research interests center on the fundamental differences between normal cells and cancer cells that can allow the development of novel therapeutic strategies.
In addition to his positions as Director of the UCSF Helen Diller Family Comprehensive Cancer Center and Associate Dean of the UCSF School of Medicine, he holds the E. Dixon Heise Distinguished Professorship in Oncology and the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research in UCSF's Department of Microbiology and Immunology. Dr. McCormick is the author of more than 260 scientific publications.
John Mekalanos is the Adele H. Lehman Professor of Microbiology and Molecular Genetics at Harvard Medical School. He has served as chair of the Microbiology and Molecular Genetics Department since 1996, and he is a member of the National Academy of Sciences and the American Academy of Microbiology. His research investigates multiple facets of bacterial pathogenesis, with an emphasis on exploring virulence gene regulation and host-pathogen interactions. Recent awards include the Drexel Medicine Prize in Infectious Disease and the Sanofi-Institut Pasteur Award for Biomedical Research.
Pardoll is Seraph Professor of Oncology, Medicine, Pathology and
Molecular Biology and Genetics at the Johns Hopkins University of
Medicine. He is Co-Director of the Cancer Immunology Program in the
Sydney Kimmel Comprehensive Cancer Center. Dr. Pardoll completed his
M.D., Ph.D., Medical Residency and Oncology Fellowship at Johns Hopkins
University. Dr. Pardoll has published over 200 papers as well as over
20 book chapters on the subject of T cell immunology and cancer
vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell,
and has served as a member of scientific advisory boards for the Cancer
Research Institute, the University of Pennsylvania Human Gene Therapy
Gene Institute, Biologic Resources Branch of the National Cancer
Institute, Harvard-Dana Farber Cancer Center, Cerus Corporation, Global
Medical Products Corporation, Genencor Corporation, Cell Genesys
Corporation, Mojave Therapeutics, the American Association of Clinical
Oncology and the American Association of Cancer Research. Dr. Pardoll
has made a number of basic advances in cellular immunology, including
the discovery of gamma-delta T cells, NKT cells and interferon-producing
killer dendritic cells. Over the past two decades, Dr. Pardoll has
studied molecular aspects of dendritic cell biology and immune
regulation, particularly related to mechanisms by which cancer cells
evade elimination by the immune system. He is an inventor of a number
of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes-based cancer vaccines.
Daniel A. Portnoy, Ph.D., University of California, Berkeley
Dr. Portnoy was elected to the National Academy of Sciences in April 2013. He is a Professor at UC Berkeley with joint appointments in the Divisions of Biochemistry & Molecular Biology, Immunology and Pathogenesis, Infectious Diseases, and Microbial Biology. He is also the Associate Director of the Berkeley Center for Emerging and Neglected Diseases. Dr. Portnoy carried out his doctoral studies at the University of Washington and Stanford, and postdoctoral studies at Rockefeller University. He has held faculty positions at Washington University and the University of Pennsylvania.
He has published over 100 papers in the areas of microbial pathogenesis and recently co-authored the section on L. monocytogenes in Harrison's Principles of Internal Medicine. Dr. Portnoy has served on Editorial Boards for Infection & Immunity, Journal of Experimental Medicine, Annual Review of Cell and Developmental Biology, Cellular Microbiology, Molecular Microbiology and PLoS Pathogens.
Dr. Portnoy studies the microbiology and immunology of intracellular pathogens with a focus on the pathogenesis of Listeria monocytogenes. He is an expert on L. monocytogenes genetics, cell biology, and immunobiology and his lab was instrumental in the development of L. monocytogenes as a vector for cancer vaccines.
Dr. Portnoy has received numerous awards and honors including the Eli Lilly and Company Research Award in Microbiology & Immunology, NIH Merit Award, Gordon Conference Chair, Honorary Doctoral from Sweden, Fellow, American Academy of Microbiology, Senior Scholar Award in Global Infectious Diseases from the Ellison Foundation, and numerous honorary keynote lectures.
Mike Powell, Ph.D., Sofinnova Ventures
Mike Powell, Ph.D., is an Advisor to Aduro. Dr. Powell has more than 25 years of pharmaceutical development experience, and he has focused interest in clinical-stage product companies, particularly in the oncology, endocrine, and neurology areas. He joined Sofinnova Ventures as a General Partner in 1997 as a member of the Life Science investment team.
Prior to becoming a venture capitalist, Mike worked on 20 clinical products and authored almost 100 papers and books, including a 1,000-page treatise on vaccine design.
Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at San Francisco General Hospital. Dr. Sherwin currently serves as a director of Biogen Idec, Neurocrine Biosciences, Rigel Pharmaceuticals, Verastem and Vical and is also a member of the board and chairman emeritus of the Biotechnology Industry Organization.
Previously Dr. Sherwin was chairman and chief executive officer of Cell Genesys, a cancer immunotherapy company, from 1990 until the company’s merger with BioSante Pharmaceuticals in 2009. He was also a co-founder and chairman of Abgenix, an antibody company which was acquired by Amgen in 2006, and co-founder and chairman of Ceregene, a gene therapy company which was acquired by Sangamo Biosciences in 2013. From 1983 to 1990, Dr. Sherwin held various positions in clinical research at Genentech, most recently that of vice president. Prior to 1983, he was on the staff of the National Cancer Institute. Dr. Sherwin holds a B.A. in biology summa cum laude from Yale University and an M.D. from Harvard Medical School, and is board-certified in internal medicine and medical oncology.